The anti-tumor effects of IL-18 through activation of lymphocytes has been studied for many years29, and prompted the opening of clinical trials with systemic administration of recombinant human IL-18 to treat advanced cancers, e.g., renal cell carcinoma, melanoma, or Hodgkin’s lymphoma32,33. Here, IL18 is linked to renal cell carcinoma.